Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.45 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458243 | 0.76 | ALDH1A1 (0.53) | L3MBTL1FFAR2HTT | |
| SCHEMBL12637374 | 0.76 | SIGMAR1 (0.62) | L3MBTL1APAF1MME | |
| SCHEMBL1878623 | 0.76 | SIGMAR1 (0.62) | L3MBTL1APAF1MME | |
| SCHEMBL8197333 | 0.76 | SIGMAR1 (0.62) | L3MBTL1APAF1MME | |
| SCHEMBL1881900 | 0.76 | SIGMAR1 (0.62) | L3MBTL1APAF1MME | |
| SCHEMBL12637371 | 0.76 | SIGMAR1 (0.62) | L3MBTL1APAF1MME | |
| SCHEMBL27710941 | 0.74 | L3MBTL1 (0.47) | NAALAD2L3MBTL1PIN1KEAP1FFAR2 | |
| SCHEMBL652495 | 0.73 | MEN1 (0.56) | APAF1MME | |
| SCHEMBL16017459 | 0.71 | MMP9 (0.60) | MME | |
| SCHEMBL17530041 | 0.71 | MMP9 (0.55) | APAF1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | NAALAD2 64/4885MMEL1 83/4885L3MBTL1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.